Page 3 - Dtx Pharma News Today

The top asset Novartis is picking up through the deal is DtX Pharma’s Fatty Acid Ligand Conjugated OligoNucleotide (FALCON) platform.

DTx Pharma is a preclinical stage biotechnology company that focuses on developing siRNA therapies for neuroscience indications, leveraging its proprietary…

BioPharma

/PRNewswire/ -- DelveInsights Progressive Supranuclear Palsy Market Insights report includes a comprehensive understanding of current treatment practices,...

News and commentary from the world of neurology and neuroscience

The FDA has granted orphan drug designation to DTx-1252, an investigational small interfering RNA therapeutic to treat Charcot-Marie-Tooth disease type 1A.According to a DTx Pharma press release, the novel therapy is part of the company’s Fatty Acid Ligand Conjugated OligoNucleotides (FALCON) platform, which uses fatty acids to improve biodistribution and cellular uptake of RNA-based

Investment will enable pHion to progress its lead program into the clinic Transaction builds on invoX's initial investment in 2021 invoX Pharma Limited ("invoX")a U.K.-based wholly-owned subsidiary

InvoX Pharma increases investment in pHion Therapeutics to further develop next generation of mRNA vaccinesInvestment will enable pHion to progress its lead program into the clinicTransaction builds on invoX’s initial investment in 2021 LONDON, United Kingdom, June, 1, 2023: invoX Pharma Limited (“i...

Investment will enable pHion to progress its lead program into the clinicTransaction builds on invoX’s initial investment in 2021LONDON--(BUSINESS WIRE)--invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline...

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm's subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASHSino Biopharm